Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
2420- SK,    Pyruvate kinase M2 regulates mitochondrial homeostasis in cisplatin-induced acute kidney injury
- in-vivo, AKI, NA
PKM2↓, other↝,
2419- SK,    Regulation of glycolysis and the Warburg effect in wound healing
- in-vivo, Nor, NA
Glycolysis↓, GLUT1↓, GLUT3↓, HK2↓, HK1↓, PFK1↓, PFK2↓, PKM2↓, lactateProd↓, GlucoseCon↓,
2418- SK,    Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2
- in-vitro, HCC, SMMC-7721 cell - in-vitro, HCC, HUH7 - in-vitro, HCC, HepG2
tumCV↓, GlucoseCon↓, lactateProd↓, ChemoSen↑, PKM2↓, Glycolysis↓,
2417- SK,    Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H446
TumCP↓, TumCMig↓, TumCI↓, GlucoseCon↓, lactateProd↓, PFKFB2↓, Warburg↓, GLUT1∅, LDHA∅, PKM2∅, GLUT3∅, PDH∅,
2416- SK,    Shikonin induces cell death by inhibiting glycolysis in human testicular cancer I-10 and seminoma TCAM-2 cells
- in-vitro, Testi, TCAM-2
MMP↓, ROS↑, lactateProd↓, Bcl-2↓, cl‑Casp3↓, PKM2↓, GLUT1↓, HK2↓, LC3B↑,
2415- SK,    Shikonin induces programmed death of fibroblast synovial cells in rheumatoid arthritis by inhibiting energy pathways
- in-vivo, Arthritis, NA
Apoptosis?, TumAuto↑, ROS↑, ATP↓, Glycolysis↓, PI3K↓, Akt↓, mTOR↓, *Apoptosis↓, *Inflam↓, *TNF-α↓, *IL6↓, *IL8↓, *IL10↓, *IL17↓, *hepatoP↑, *RenoP↑, PKM2↓, GLUT1↓, HK2↓,
2354- SK,    PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation
- in-vivo, Sepsis, NA
PKM2↓, *PKM2↓, *IL1β↓, *IL18↓, *HMGB1↓, *Casp1↓, *NLRP3↓, *AIM2↓, *p‑eIF2α↓, *Sepsis↓,
2355- SK,    Pharmacological properties and derivatives of shikonin-A review in recent years
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, TumAuto↑, Necroptosis↑, ROS↑, TrxR1↓, PKM2↓, RIP1↓, RIP3↓, Src↓, FAK↓, PI3K↓, Akt↓, mTOR↓, GRP58↓, MMPs↓, ATF2↓, cl‑PARP↑, Casp3↑, p‑p38↑, p‑JNK↑, p‑ERK↓,
2370- SK,    The role of pyruvate kinase M2 in anticancer therapeutic treatments
- Review, Var, NA
Glycolysis↓, PKM2↓, EGFR↓, PI3K↓, p‑Akt↓, Hif1a↓,
2356- SK,    ESM1 enhances fatty acid synthesis and vascular mimicry in ovarian cancer by utilizing the PKM2-dependent warburg effect within the hypoxic tumor microenvironment
- in-vitro, Ovarian, CaOV3 - in-vitro, Ovarian, OV90 - in-vivo, NA, NA
PKM2↓, Glycolysis↓, FASN↓, lactateProd↓, Warburg↓, TumCG↓, VM↓,
2357- SK,    GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism
- Study, HCC, NA - in-vivo, NA, NA
AntiTum↑, GTPBP4↓, PKM2↓, lactateProd↓, GlucoseCon↓, Glycolysis↓, E-cadherin↑, TumCG↓,
2358- SK,    SIRT1 improves lactate homeostasis in the brain to alleviate parkinsonism via deacetylation and inhibition of PKM2
- in-vivo, Park, NA
*eff↑, *PKM2↓, *motorD↑, *lactateProd↓,
2360- SK,    Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway
- in-vitro, NPC, HONE1 - in-vitro, NPC, SUNE-1
TumCP↓, Apoptosis↑, TumCMig↓, TumCI↓, GlucoseCon↓, lactateProd↓, ATP↓, PKM2↓, PI3K↓, Akt↓, MMP3↓, MMP9↓, TIMP1↑,
2361- SK,    Natural shikonin and acetyl-shikonin improve intestinal microbial and protein composition to alleviate colitis-associated colorectal cancer
- in-vivo, CRC, NA
GutMicro↑, Dose↝, IL1β↓, IL6↓, TNF-α↓, PKM2↓,
2362- SK,    RIP1 and RIP3 contribute to shikonin-induced glycolysis suppression in glioma cells via increase of intracellular hydrogen peroxide
- in-vitro, GBM, U87MG - in-vivo, GBM, NA - in-vitro, GBM, U251
RIP1↑, RIP3↑, Glycolysis↓, G6PD↓, HK2↓, PKM2↓, H2O2↑, GSH↓, ROS↑,
2363- SK,    Inhibition of PKM2 by shikonin impedes TGF-β1 expression by repressing histone lactylation to alleviate renal fibrosis
- in-vivo, CKD, NA
PKM2↓, lactateProd↓, TGF-β↓,
2364- SK,    Pyruvate Kinase M2 Mediates Glycolysis Contributes to Psoriasis by Promoting Keratinocyte Proliferation
- in-vivo, PSA, NA
eff↑, lactateProd↓, PKM2↓,
2211- SK,    Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways
- in-vivo, ostP, NA
*BMD↑, *p‑NF-kB↓, *p‑p50↓, *p‑p65↓, *p‑ERK↓, *p‑cJun↓, *p‑p38↓,
2234- SK,    Shikonin Suppresses Cell Tumorigenesis in Gastric Cancer Associated with the Inhibition of c-Myc and Yap-1
- in-vitro, GC, NA
TumCP↓, TumCI↓, TumCMig↓, cMyc↓, YAP/TEAD↓,
2233- SK,    Clinical trial on the effects of shikonin mixture on later stage lung cancer
- Trial, Lung, NA
TumVol↓, Remission↑, OS↑, QoL↑, Weight↑, *toxicity∅,
2232- SK,    Shikonin Induces Autophagy and Apoptosis in Esophageal Cancer EC9706 Cells by Regulating the AMPK/mTOR/ULK Axis
- in-vitro, ESCC, EC9706
tumCV↓, TumCMig↓, TumCI↓, TumAuto↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑PARP↑, AMPK↑, mTOR↑, TumVol↓, OS↑, LC3I↑,
2231- SK,    Shikonin Exerts Cytotoxic Effects in Human Colon Cancers by Inducing Apoptotic Cell Death via the Endoplasmic Reticulum and Mitochondria-Mediated Pathways
- in-vitro, CRC, SNU-407
Apoptosis↑, ER Stress↑, PERK↑, eIF2α↑, CHOP/DDIT3↑, mt-Ca+2↑, MMP↓, Bcl-2↓, Casp3↑, Casp9↑, ERK↑, JNK↑, p38↓,
2230- SK,    Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
TumCG↓, Bcl-2↓, ROS↑, Bcl-xL↓, MMP↓, Casp↑, selectivity↑, cycD1/CCND1↓, TumCCA↑, eff↓,
2191- SK,    Shikonin Suppresses Skin Carcinogenesis via Inhibiting Cell Proliferation
- in-vitro, Melanoma, NA
PKM2↓, ATF4↓, CDK4↓, COX2/PTGS2↓, MAPK↓,
2201- SK,    Shikonin promotes ferroptosis in HaCaT cells through Nrf2 and alleviates imiquimod-induced psoriasis in mice
- in-vitro, PSA, HaCaT - in-vivo, NA, NA
*eff↑, *IL6↓, *IL17↓, *TNF-α↓, *lipid-P↑, *NRF2↓, *HO-1↝, *NCOA4↝, *GPx4↓, *Ferroptosis↓, *Inflam↓, *ROS↓, *Iron↓,
2200- SK,    Shikonin inhibits the growth of anaplastic thyroid carcinoma cells by promoting ferroptosis and inhibiting glycolysis
- in-vitro, Thyroid, CAL-62 - in-vitro, Thyroid, 8505C
NF-kB↓, GPx4↓, TrxR1↓, PKM2↓, GLUT1↓, Glycolysis↓, Ferroptosis↑, GlucoseCon↓, lactateProd↓, ROS↑,
2199- SK,    Induction of Ferroptosis by Shikonin in Gastric Cancer via the DLEU1/mTOR/GPX4 Axis
- in-vitro, GC, NA
ROS↑, lipid-P↑, Iron↑, MDA↑, GPx4↓, Ferritin↓, DLEU1↓, mTOR↓, Ferroptosis↑,
2198- SK,    Shikonin suppresses proliferation of osteosarcoma cells by inducing ferroptosis through promoting Nrf2 ubiquitination and inhibiting the xCT/GPX4 regulatory axis
- in-vitro, OS, MG63 - in-vitro, OS, 143B
TumCP↓, TumCCA↑, Ferroptosis↑, Iron↑, ROS↑, lipid-P↑, MDA↑, mtDam↑, NRF2↓, xCT/SLC7A11↓, GPx4↓, GSH/GSSG↓, Keap1↑,
2197- SK,    Shikonin derivatives for cancer prevention and therapy
- Review, Var, NA
ROS↑, Ca+2↑, BAX↑, Bcl-2↓, MMP9↓, NF-kB↓, PKM2↓, Hif1a↓, NRF2↓, P53↑, DNMT1↓, MDR1↓, COX2/PTGS2↓, VEGF↓, EMT↓, MMP7↓, MMP13↓, uPA↓, RIP1↑, RIP3↑, Casp3↑, Casp7↑, Casp9↑, P21↓, DFF45↓, TRAIL↑, PTEN↑, mTOR↓, AR↓, FAK↓, Src↓, Myc↓, RadioS↑,
2196- SK,    Research progress in mechanism of anticancer action of shikonin targeting reactive oxygen species
- Review, Var, NA
*ALAT↓, *AST↓, *Inflam?, *EMT↑, ROS?, TrxR1↓, PERK↑, eIF2α↑, ATF4↑, CHOP/DDIT3↑, IRE1↑, JNK↑, eff↝, DR5↑, Glycolysis↓, PKM2↓, ChemoSen↑, GPx4↓, HO-1↑,
2195- SK,    Shikonin induces ferroptosis in osteosarcomas through the mitochondrial ROS-regulated HIF-1α/HO-1 axis
- in-vitro, OS, NA
TumCP↓, Ferroptosis↓, Hif1a↑, HO-1↑, Iron↑, ROS↑, GSH/GSSG↓, GPx4↓,
2194- SK,    Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, EC9706 - in-vivo, NA, NA
tumCV↓, TumCCA↑, Apoptosis↑, EGFR↓, PI3K↓, Hif1a↓, PKM2↓, cycD1/CCND1↓, AntiTum↑,
2193- SK,    Shikonin Suppresses Lymphangiogenesis via NF-κB/HIF-1α Axis Inhibition
- in-vitro, Nor, HMVEC-dLy
*NF-kB↓, *Hif1a↓, other↓,
2192- SK,    Shikonin Inhibits Tumor Growth of ESCC by suppressing PKM2 mediated Aerobic Glycolysis and STAT3 Phosphorylation
- in-vitro, ESCC, KYSE-510 - in-vitro, ESCC, Eca109 - in-vivo, NA, NA
TumCP↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PKM2↓, p‑PKM2↓, p‑STAT3↓, GLUT1↓, HK2↓, TumW↓,
2228- SK,    Shikonin induced Apoptosis Mediated by Endoplasmic Reticulum Stress in Colorectal Cancer Cells
- in-vitro, CRC, HCT116 - in-vitro, CRC, HCT15 - in-vivo, NA, NA
Apoptosis↑, Bcl-2↓, Casp3↑, Casp9↑, cl‑PARP↑, GRP78/BiP↑, PERK↑, eIF2α↑, ATF4↑, CHOP/DDIT3↑, JNK↑, eff↓, ER Stress↑, ROS↑, TumCG↓,
2190- SK,    Shikonin exerts antitumor activity by causing mitochondrial dysfunction in hepatocellular carcinoma through PKM2-AMPK-PGC1α signaling pathway
- in-vitro, HCC, HCCLM3
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, MMP↓, ROS↑, OCR↓, ATP↓, PKM2↓,
2189- SK,    PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells
- in-vitro, Melanoma, NA
PKM2↓, chemoPv↑, eff↝, lactateProd↓, ROS↑, *ROS?, *PKM2↓,
2188- SK,    Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment
- Review, Var, NA
ROS↑, EGFR↓, PI3K↓, Akt↓, angioG↓, Apoptosis↑, Necroptosis↑, GSH↓, Ca+2↓, MMP↓, ERK↓, p38↑, proCasp3↑, eff↓, VEGF↓, FOXO3↑, EGR1↑, SIRT1↑, RIP1↑, RIP3↑, BioAv↓, NF-kB↓, Half-Life↓,
2187- SK,  VitK3,    Shikonin, vitamin K3 and vitamin K5 inhibit multiple glycolytic enzymes in MCF-7 cells
- in-vitro, BC, MCF7
Glycolysis↓, PKM2↓,
2186- SK,    Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line
- in-vitro, HCC, HepG2 - in-vitro, HCC, HCCLM3
Glycolysis↓, PKM2↓, Apoptosis↑, ROS↑, OXPHOS⇅, eff↓,
2185- SK,    Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis
- in-vitro, Lung, LLC1 - in-vitro, Melanoma, B16-BL6 - in-vivo, NA, NA
Glycolysis↓, GlucoseCon↓, lactateProd↓, PKM2↓, selectivity↑, Warburg↓, TumVol↓, TumW↓,
2184- SK,  Cisplatin,    PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis
- in-vitro, CRC, T24/HTB-9
PKM2↓, ChemoSen↑, Necroptosis↑,
2183- SK,    Shikonin Inhibites Migration and Invasion of Thyroid Cancer Cells by Downregulating DNMT1
- in-vitro, Thyroid, TPC-1
TumCMig↓, TumCI↓, PTEN↑, DNMT1↓,
2182- SK,  Cisplatin,    Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway
- in-vitro, Lung, A549 - in-vitro, Lung, PC9 - in-vivo, NA, NA
tumCV↓, TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, PKM2↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, ChemoSen↑, TumVol↓, TumW↓, GLUT1↓,
2181- SK,    Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2
- in-vitro, BC, MCF7 - in-vitro, Lung, A549 - in-vitro, Cerv, HeLa
Glycolysis↓, lactateProd↓, GlucoseCon↓, PKM2↓, LDH∅,
2203- SK,    Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation
- in-vitro, Lung, NA
TumCP↓, Apoptosis↓, TumCMig↓, TumCI↓, Ferroptosis↑, ERK↓, GPx4↓, 4-HNE↑, ROS↑, GSH↓, ATF3↑, HDAC1↓, ac‑Histones↑,
2229- SK,    Shikonin induces apoptosis and prosurvival autophagy in human melanoma A375 cells via ROS-mediated ER stress and p38 pathways
- in-vitro, Melanoma, A375
Apoptosis↑, TumAuto↑, TumCP↓, TumCCA↑, P21↑, cycD1/CCND1↓, ER Stress↑, p‑eIF2α↑, CHOP/DDIT3↑, cl‑Casp3↑, p38↑, LC3B-II↑, Beclin-1/ATG6↑, ROS↑, eff↓,
2227- SK,    Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species
- in-vitro, GC, BGC-823 - in-vitro, GC, SGC-7901 - in-vitro, Nor, GES-1
selectivity↑, TumCP↓, TumCD↑, ROS↑, MMP↓, Casp↑, Cyt‑c↑, Endon↑, AIF↑, eff↓, ChemoSen↑, TumCCA↑, GSH/GSSG↓, lipid-P↑,
2226- SK,    Shikonin, a Chinese plant-derived naphthoquinone, induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species: A potential new treatment for hepatocellular carcinoma
- in-vitro, HCC, HUH7 - in-vitro, HCC, Bel-7402
selectivity↑, ROS↑, eff↓, Akt↓, RIP1↓, NF-kB↓,
2225- SK,    Shikonin protects skin cells against oxidative stress and cellular dysfunction induced by fine particulate matter
- in-vitro, Nor, HaCaT
*antiOx↑, *ROS↓, *GSH↑, *GCLC↑, *GSS↑, *Akt↑, *NRF2↑,

Showing Research Papers: 7501 to 7550 of 8276
Prev Page 151 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8276

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

4-HNE↑, 1,   ATF3↑, 1,   Ferroptosis↓, 1,   Ferroptosis↑, 4,   GPx4↓, 6,   GSH↓, 3,   GSH/GSSG↓, 3,   H2O2↑, 1,   HK1↓, 1,   HO-1↑, 2,   Iron↑, 3,   Keap1↑, 1,   lipid-P↑, 3,   MDA↑, 2,   NRF2↓, 2,   OXPHOS⇅, 1,   ROS?, 1,   ROS↑, 19,   TrxR1↓, 3,   xCT/SLC7A11↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   ATP↓, 3,   MMP↓, 6,   mtDam↑, 1,   OCR↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   cMyc↓, 1,   FASN↓, 1,   G6PD↓, 1,   GlucoseCon↓, 10,   Glycolysis↓, 15,   ac‑Histones↑, 1,   HK2↓, 5,   lactateProd↓, 15,   LDH∅, 1,   LDHA∅, 1,   PDH∅, 1,   PFK1↓, 1,   PFK2↓, 1,   PFKFB2↓, 1,   PKM2↓, 29,   PKM2∅, 1,   p‑PKM2↓, 1,   SIRT1↑, 1,   Warburg↓, 3,  

Cell Death(tgid=5) ⓘ

Akt↓, 5,   p‑Akt↓, 1,   Apoptosis?, 1,   Apoptosis↓, 1,   Apoptosis↑, 11,   ATF2↓, 1,   BAX↑, 2,   Bcl-2↓, 6,   Bcl-xL↓, 1,   Casp↑, 2,   Casp3↑, 4,   cl‑Casp3↓, 1,   cl‑Casp3↑, 2,   proCasp3↑, 1,   Casp7↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 3,   Cyt‑c↑, 1,   DR5↑, 1,   Endon↑, 1,   Ferroptosis↓, 1,   Ferroptosis↑, 4,   GRP58↓, 1,   JNK↑, 3,   p‑JNK↑, 1,   MAPK↓, 1,   Myc↓, 1,   Necroptosis↑, 3,   p38↓, 1,   p38↑, 2,   p‑p38↑, 1,   RIP1↓, 2,   RIP1↑, 3,   TRAIL↑, 1,   TumCD↑, 1,   YAP/TEAD↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

DLEU1↓, 1,   other↓, 1,   other↝, 1,   tumCV↓, 4,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 4,   eIF2α↑, 3,   p‑eIF2α↑, 1,   ER Stress↑, 3,   GRP78/BiP↑, 1,   IRE1↑, 1,   PERK↑, 3,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   LC3B↑, 1,   LC3B-II↑, 1,   LC3I↑, 1,   TumAuto↑, 4,  

DNA Damage & Repair(tgid=10) ⓘ

DFF45↓, 1,   DNMT1↓, 2,   P53↑, 1,   cl‑PARP↑, 3,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 3,   P21↓, 1,   P21↑, 1,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 1,   ERK↓, 2,   ERK↑, 1,   p‑ERK↓, 1,   FOXO3↑, 1,   GTPBP4↓, 1,   HDAC1↓, 1,   mTOR↓, 4,   mTOR↑, 1,   PI3K↓, 6,   PTEN↑, 2,   Src↓, 2,   p‑STAT3↓, 1,   TumCG↓, 4,  

Migration(tgid=13) ⓘ

Ca+2↓, 1,   Ca+2↑, 1,   mt-Ca+2↑, 1,   E-cadherin↑, 1,   FAK↓, 2,   MMP13↓, 1,   MMP3↓, 1,   MMP7↓, 1,   MMP9↓, 2,   MMPs↓, 1,   RIP3↓, 1,   RIP3↑, 3,   TGF-β↓, 1,   TIMP1↑, 1,   TumCI↓, 8,   TumCMig↓, 9,   TumCP↓, 12,   uPA↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   ATF4↓, 1,   ATF4↑, 2,   EGFR↓, 3,   EGR1↑, 1,   Hif1a↓, 3,   Hif1a↑, 1,   VEGF↓, 2,   VM↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 6,   GLUT1∅, 1,   GLUT3↓, 1,   GLUT3∅, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 2,   IL1β↓, 1,   IL6↓, 1,   NF-kB↓, 4,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   ChemoSen↑, 5,   Dose↝, 1,   eff↓, 7,   eff↑, 1,   eff↝, 2,   Half-Life↓, 1,   MDR1↓, 1,   RadioS↑, 1,   selectivity↑, 4,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   EGFR↓, 3,   Ferritin↓, 1,   GutMicro↑, 1,   IL6↓, 1,   LDH∅, 1,   Myc↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 2,   chemoPv↑, 1,   OS↑, 2,   QoL↑, 1,   Remission↑, 1,   TumVol↓, 4,   TumW↓, 3,   Weight↑, 1,  
Total Targets: 184

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Ferroptosis↓, 1,   GCLC↑, 1,   GPx4↓, 1,   GSH↑, 1,   GSS↑, 1,   HO-1↝, 1,   Iron↓, 1,   lipid-P↑, 1,   NRF2↓, 1,   NRF2↑, 1,   ROS?, 1,   ROS↓, 2,  

Metal & Cofactor Biology(tgid=2) ⓘ

NCOA4↝, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   lactateProd↓, 1,   PKM2↓, 3,  

Cell Death(tgid=5) ⓘ

Akt↑, 1,   Apoptosis↓, 1,   Casp1↓, 1,   Ferroptosis↓, 1,   p‑p38↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

p‑cJun↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

p‑eIF2α↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↑, 1,   p‑ERK↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

AIM2↓, 1,   HMGB1↓, 1,   IL10↓, 1,   IL17↓, 2,   IL18↓, 1,   IL1β↓, 1,   IL6↓, 2,   IL8↓, 1,   Inflam?, 1,   Inflam↓, 2,   NF-kB↓, 1,   p‑NF-kB↓, 1,   p‑p50↓, 1,   p‑p65↓, 1,   TNF-α↓, 2,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   BMD↑, 1,   IL6↓, 2,  

Functional Outcomes(tgid=23) ⓘ

hepatoP↑, 1,   motorD↑, 1,   RenoP↑, 1,   toxicity∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

Sepsis↓, 1,  
Total Targets: 53

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page